Literature DB >> 20099518

Exploration of skin permeation mechanism of frusemide with proniosomes.

A Azeem1, F J Ahmad, S Talegaonkar.   

Abstract

The present study explored the transdermal permeation enhancing mechanism of non-ionic surfactant vesicles (proniosomes) of frusemide across rat skin. Fourier Transform Infrared Spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), activation energy and histological examination were carried out to study the mode of action of the optimized proniosome formulations PGS [Span 40:soyalecithin:cholesterol (4.5:4.5:1)] and PGD [Span 40:dicetylphosphate:cholesterol (4.5:4.5:1)]. The IR spectra showed a prominent decrease in peak areas and heights of CH2 stretchings but did not show shift of these peaks and shift in amide bands. DSC studies also confirmed the IR findings. It was concluded that the proniosomes disrupted the lipid bilayer by extracting the lipids thereby creating pathways for drug penetration. The significant decrease in activation energy for frusemide permeation across rat skin indicated the SC lipid bilayers were significantly disrupted (p<0.05). Histological investigations were carried out. Disruption and extraction of lipid bilayers as distinct voids and empty spaces were visible in the epidermal region. Overall, our findings suggested that proniosomal formulations offer a promising means for non-invasive delivery of frusemide, especially due to their ability to modulate drug transfer and serve as non-toxic permeation enhancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20099518

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  2 in total

1.  Formulation and optimization of clotrimazole-loaded proniosomal gel using 3(2) factorial design.

Authors:  Litha Thomas; Vidya Viswanad
Journal:  Sci Pharm       Date:  2012-05-03

Review 2.  A review on proniosomal drug delivery system for targeted drug action.

Authors:  G V Radha; T Sudha Rani; B Sarvani
Journal:  J Basic Clin Pharm       Date:  2013-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.